Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen M Mahoney

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Nature Immunology|December 12, 2019
Acidity changes immunology: a new VISTA pathwayKathleen M Mahoney, Gordon J Freeman
Oncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B Atkins
Nature Reviews. Immunology|January 23, 2020
The importance of exosomal PDL1 in tumour immune evasionDhouha Daassi, Kathleen M Mahoney, Gordon J Freeman
Trends in Molecular Medicine|May 14, 2016
Learning from PD-1 Resistance: New Combination StrategiesXia Bu, Kathleen M Mahoney, Gordon J Freeman
Clinical Therapeutics|April 1, 2015
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M Mahoney, Gordon J Freeman, David F McDermott
Nature Reviews. Drug Discovery|August 1, 2015
Combination cancer immunotherapy and new immunomodulatory targetsKathleen M Mahoney, Paul D Rennert, Gordon J Freeman
Trends in Immunology|January 26, 2021
VISTA: A Mediator of Quiescence and a Promising Target in Cancer ImmunotherapyLong Yuan, Jahnavi Tatineni, Kathleen M Mahoney, et al.
Environmental and Molecular Mutagenesis|August 21, 2003
Frameshift mutations induced by three classes of acridines in the lacZ reversion assay in Escherichia coli: potency of responses and relationship to slipped mispairing modelsGeorge R Hoffmann, Margaret A Calciano, Bryan M Lawless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2013
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complicationKathleen M Mahoney, Allison Ackerman, Daniel C Cho, et al.
Cancer|June 18, 2011
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancerHeather L McArthur, Kathleen M Mahoney, Patrick G Morris, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Nature Immunology|December 12, 2019
Acidity changes immunology: a new VISTA pathwayKathleen M Mahoney, Gordon J Freeman
Oncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B Atkins
Nature Reviews. Immunology|January 23, 2020
The importance of exosomal PDL1 in tumour immune evasionDhouha Daassi, Kathleen M Mahoney, Gordon J Freeman
Trends in Molecular Medicine|May 14, 2016
Learning from PD-1 Resistance: New Combination StrategiesXia Bu, Kathleen M Mahoney, Gordon J Freeman
Clinical Therapeutics|April 1, 2015
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M Mahoney, Gordon J Freeman, David F McDermott
Nature Reviews. Drug Discovery|August 1, 2015
Combination cancer immunotherapy and new immunomodulatory targetsKathleen M Mahoney, Paul D Rennert, Gordon J Freeman
Trends in Immunology|January 26, 2021
VISTA: A Mediator of Quiescence and a Promising Target in Cancer ImmunotherapyLong Yuan, Jahnavi Tatineni, Kathleen M Mahoney, et al.
Environmental and Molecular Mutagenesis|August 21, 2003
Frameshift mutations induced by three classes of acridines in the lacZ reversion assay in Escherichia coli: potency of responses and relationship to slipped mispairing modelsGeorge R Hoffmann, Margaret A Calciano, Bryan M Lawless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2013
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complicationKathleen M Mahoney, Allison Ackerman, Daniel C Cho, et al.
Cancer|June 18, 2011
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancerHeather L McArthur, Kathleen M Mahoney, Patrick G Morris, et al.
Pageof 3